All News

lung%2Cbright.jpg

ICYMI: Effective Treatments for Rheumatoid Arthritis ILD

d Michael Putman, MD, MSCI

The American College of Rheumatology guidelines for the diagnosis and management of interstitial lung disease, which includes rheumatoid arthritis interstitial lung disease (RA-ILD), has been one of the most controversial topics in the runup to ACR Convergence.

Read Article
RheumNow Podcast square

RheumNow Podcast – Bill of Rights (12.15.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Two major reports on fatigue and fibromyalgia misfired, and "ankylosing spondylitis" is sent to the Rheumatology dead word cemetery. 

Read Article
LBP_0.jpg

Gender Gap Confirmed for TNF Inhibitor Response in Axial SpA

d MedPage Today

Men with axial spondyloarthritis (axSpA) were more likely than women to obtain substantial relief with tumor necrosis factor (TNF) inhibitors, a multinational study indicated.

Read Article
psA.fil_.Hands_.jpg

ICYMI: Bimekizumab is Coming…in Third Place

d Michael Putman, MD, MSCI

Of the many exciting advancements for patients with psoriatic arthritis at ACR Convergence, one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab. Nearly two dozen bimekizumab abstracts will be featured at this year’s meeting and it recently received authorization in Europe and the U.S. for psoriasis. That makes this the year I plan to figure out where this drug will be useful for my patients with PsA. 

Read Article
am pm pillbox containing pills in each slot

ICYMI: Methotrexate: shall we split up?

d Aurelie Najm, MD, PhD

Methotrexate is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg. In the SMART study, Prasad et al. present the first RCT comparing either single dose (25 mg) or split-dose (10 mg morning, 15 mg evening, same day) once weekly MTX for 24 weeks.

Read Article
FINAL DAY for early bird pricing for RheumNow Live. Take advantage of this discounted price TODAY! https://t.co/UW9SMjEBYB https://t.co/DX2SJZYkUW

Links:

Dr. John Cush RheumNow ( View Tweet)
Maryland specialty clinic eval 1395 Lyme pts & saw marked differences between blacks & whites. Black patients had 5 fold (OR 4.93) higher risk of disseminated LD & delay in Abx Rx. Dissem Dz also more likely in men (OR, 1.6) EM Rash harder to spot https://t.co/Hhxr7hscaL https://t.co/J46JvHwRmc

Links:

Dr. John Cush RheumNow ( View Tweet)
Clinical Practice Res Database studied 51K gout pts before ULT therapy, 36% had  ≥ 1 recurrent flares, 17% flared w/in 12 mos of Dx. Flares risk: Male, blacks, obese, CHF, CKD, CVD, diuretics, Hi SUA (HR 4.6). Only 28% Given ULT w/in 12 mos of Dx https://t.co/TAHBDxA6Th https://t.co/rwztpe7y2r

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Eosinophilia in RA High Eosinophil counts in Stable RA - what's the differential Dx?. https://t.co/au606vNQob https://t.co/VJneBfGr4P

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Here at Last: Treatment Options for VEXAS We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but prior to #ACR23 there has been relatively little to say about how to treat it. https://t.co/FnygxtDwx8 https://t.co/2j1nbsAAp0

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab Acute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA), affecting up to 50% of patients in some age groups. https://t.co/wn5iDXibzi https://t.co/IVtKwdYDwN

Links:

Dr. John Cush RheumNow ( View Tweet)
Programmed-cell-death 1 (PD-1) expression on T-cells is assoc w/ activation & exhaustion. The exhausted phenotype of PD-1+CD8+ T cells add to the pathogenesis of active idiopathic inflammatory myositis. https://t.co/TRgtYCbnf2 https://t.co/7xgBU3apmy

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR 2023 Recommendations on Fatigue Fatigue is highly prevalent in inflammatory rheumatic and musculoskeletal diseases (I-RMDs) patients, is often unaddressed and yet it has significant effects on patient quality of life. https://t.co/e2pP8bt9jg https://t.co/7R58j1oZKR

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is rapidly approaching. Are you registered? Amongst our 25 speakers, Dr. Kahlenberg will cover Biology and RX of Lupus Flares. Dr. Fava will cover Current/Future Biomarkers in SLE, all in a session on The Future of SLE Management. https://t.co/aJ8ciU3auI https://t.co/0WgD0dmLiE

Links:

Dr. John Cush RheumNow ( View Tweet)

IL-18 excess is assoc. w/ autoinflammatory Dz, "IL-18opathies". High IL-18 associated w/ #MAS & PSTPIP1-related diseases (eg, PAPA syndr. Pyogenic arthritis, pyoderma gangrenosum, acne)IL-18 binding protein is a biomarker of IFNγ activity. https://t.co/dy3xHdgTXX https://t.co/qBvCHvtsu7

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA undergoing lumbar degenerative disease (LDD) surgery have 2 fold higher risk of VTE. National Inpatient study 471,283 LDD surgeries showed PsA had higher overall morbidity (9 % v 7 %), VTE (1.4 % v 0.7 %), unfavorable D/C(21% v. 17 %). https://t.co/C0eimmwEmm https://t.co/58PoJOJEeY

Links:

Dr. John Cush RheumNow ( View Tweet)
RA pts more likely to get autoimmune thyroid Dz (AITD), but after dx, AITD risk signif. drops (HR 0.81), suggesting RA Rx lowers AITD risk; greater drop in biologic Rx RA (HR 0.54).Swiss registry compared 13,731 new-onset RA pts to 63,201 matched controls https://t.co/n0n2EfUyqR https://t.co/yMMHvYRsyY

Links:

Dr. John Cush RheumNow ( View Tweet)
Cannabis Use in Rheumatic Diseases Dr. Janet Pope discusses several abstracts presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/C2vbbERoHZ https://t.co/XeiS0cJjuy

Links:

Dr. John Cush RheumNow ( View Tweet)
INVIGORATE-1 Study: IV Secukinumab for Treatment of Active axSpA Dr. Atul Deodhar reports on abstract 2545 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/Fhv7dhDTJA https://t.co/Zz0PwFjOD4

Links:

Dr. John Cush RheumNow ( View Tweet)
CDC: Chronic Fatigue Syndrome 2021-2022 The current CDC report estimates that 1.3% of adults had myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), based on the most recent population based National Health Interview Survey (NHIS 2021–2022). https://t.co/4LeQ7DJPyI https://t.co/5ITG46d25M

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×